Merck (MRK) shares fell when Summit Therapeutics (SMMT) reported positive results from a Phase 3 trial of a lung cancer drug that could rival Merck's Keytruda. Summit Therapeutics shares soared to ...

Merck stock (NYSE: MRK) has gained over 65% in value since early January 2021 – jumping from levels of $70 then to around $115 now – vs. an increase of about 50% for the S&P 500 over this period.

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

Merck & Co. has launched a late-stage study of Restoret, the key asset in its recent $1.3 billion acquisition of eye-drug company EyeBio. Merck on Wednesday said the Phase 2b/3 study will evaluate ...

Merck faces significant challenges, including increased competition and regulatory scrutiny for Keytruda. Keytruda is facing potential threats from competitors like Summit Therapeutics ...

Merck & Company Inc (NYSE:MRK) was up 10% YTD as of Friday, August 30 ’24, but had been up as much as 21% at various times through the 2nd quarter, but the Q2 ’24 earnings release put a big ...

Merck's Keytruda therapy received approval from the European Union, in combination with antibody-drug Padcev, as a first-line cancer treatment. The pharmaceutical company said Tuesday that the ...

A new study has found that concentrations of essential minerals inside rhino horns are too low to provide consumers with any health benefits, questioning their use in traditional Chinese medicine.

Earlier this summer, miners accidentally unearthed the mummified remains of a woolly rhino in a quarry in the rural Oymyakonsky District of Russia. The preserved mammal’s body included soft ...

It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 5.6% over the past three months. But if you pay close attention, you might find that ...

London: Merck has stopped two separate late-stage studies of its immunotherapy Keytruda in patients with skin and lung cancers, the company said on Thursday, marking the latest set of trial ...

Mer­ck said Thurs­day morn­ing it is dis­con­tin­u­ing two Phase 3 tri­als of Keytru­da, the world’s top-sell­ing med­i­cine, af­ter in­de­pen­dent da­ta mon­i­tor­ing … ...